Boyds strengthens regulatory affairs team with the appointment of experienced toxicologist
Leading pharmaceutical and biotech product development consultancy Boyds has added to its regulatory team with the appointment of experienced toxicologist, Dr Geoffrey Rose in response to the continued increase in demand for its dedicated regulatory services.
With more than 20 years’ regulatory experience across the full clinical product lifecycle, regulatory toxicologist Geoffrey joins Boyds as Director of Regulatory Affairs.
At Boyds, Geoffrey will provide strategic regulatory advice and support to Boyds’ clients across a range of therapeutic areas and all development stages of small and large molecules, including advanced therapy medicinal products (ATMPs), biologicals and new chemical entities.
Prior to joining Boyds, Geoffrey was an independent consultant, after five years as a Senior Consultant at the NDA Group, where he provided regulatory advice at all stages of product development from lead optimisation through to market authorisation applications for small molecules, biologicals and ATMPs, as well as supporting clinical trial programmes for drug candidates.
Geoffrey’s previous roles include Senior Director of the Non-Clinical Regulatory Affairs Group at UCB, Senior Regulatory Toxicologist at Yamanouchi Europe B.V (Astellas Pharma), and Senior Regulatory Toxicologist in the Central Toxicology Laboratory at Zeneca (AstraZeneca).
Boyds’ growing regulatory affairs team, which last year won the Futures category in the coveted TOPRA Awards, has now added four new scientists this year - Dr Lucie Hwang, Regulatory Affairs Associate joined Boyds in June, and Dr Victoria Marsh, Director of Regulatory Affairs and Dr Kim Champion, Regulatory Affairs Manager, in April.
Of joining Boyds’ regulatory affairs team, Geoffrey says: “I was looking to join a well-established consultancy where I could add value, and Boyds is the perfect fit.
“Over the last 20 years of my career, the field of toxicology has changed and evolved significantly,” he explains, “there is a growing concern for the use of animals, but also a requirement for ever increasing regulations to cover innovative drug candidates. Embracing and tackling these challenges gives me the continued incentive to provide different and robust programmes to ensure regulatory compliance and subsequent drug approval.
“I am looking forward to working with the talented regulatory affairs team at Boyds across all therapeutic areas, having a major input on clients’ early development programmes, playing my part in the company’s sustained success and supporting the development of medicines for patient benefit.”
Dr Julie Warner, Vice President of Regulatory Affairs at Boyds, adds: “Our regulatory affairs team has an enviable track record and works across a number of advanced therapeutic areas. 2020 has been a year like no other, with the Boyds team supporting numerous ATMP and COVID-19 projects as well as helping our clients navigate the guidance and updated regulations ahead of the UK leaving the EU on the 31st December. We pride ourselves on our ability to provide clients with genuine strategic input as well as assisting with the preparation of regulatory documentation and guiding clients through the various procedures to bring their product to market.
“Geoffrey’s extensive expertise and experience is a welcome addition to the team, and will add real value to clients by providing them with in-house, dedicated toxicology support for their projects, helping them to reach their desired outcomes. Demand for our regulatory services continues to rise, and we are thrilled to welcome Geoffrey to the team at this busy time.”
Boyds won the Queen’s Award for Enterprise, International Trade for Outstanding Short-Term Growth in overseas sales in April 2018 and was the Business of the Year in the South Cheshire Chamber Awards 2019.